Key Highlights

Risk & Performance

Pipeline Risk Assessment

Pipeline Risk Assessment

Based on historical performance

Moderate Risk

Score: 45/100

Failure Rate

0.0%

0 terminated/withdrawn out of 5 trials

Success Rate

100.0%

+13.5% vs industry average

Late-Stage Pipeline

0%

0 trials in Phase 3/4

Results Transparency

0%

0 of 4 completed trials have results

Key Signals

Enrollment Performance

Analytics

N/A
3(100.0%)
3Total
N/A(3)

Activity Timeline

Global Presence

Loading network data...

Clinical Trials (5)

Showing 5 of 5 trials
NCT05504135Completed

Implementation of Pre-emptive Pharmacogenomics Testing in Singapore-based Private Hospital Institutions (IMPT Study)

Role: lead

NCT05562440Not ApplicableCompleted

The Perspective of Healthy Individuals on Breast Cancer Risk Prediction Report In The Indonesian Population

Role: lead

NCT05570266Completed

Genetic and Non-Genetic Breast Cancer Risk Prediction Evaluation in Indonesian Samples

Role: lead

NCT05501158Not ApplicableUnknown

CYP2D6 Genotypes and Breast Cancer Clinical Outcomes in the Indonesian Population

Role: lead

NCT04312347Not ApplicableCompleted

Tamoxifen Dose Adjustment on Indonesian Female ER+ Breast Cancer Patients Based on CYP2D6 Genotype and Endoxifen Levels

Role: lead

All 5 trials loaded